Company / R&D per Share
EyePoint, Inc. R&D per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$3.24
FY2025
5-year range
$0.96 / $3.24
FY2021-FY2025
Trend
+145.6%
vs FY2024
Sector context
#21 of 108
Health Care
What the data says
EyePoint, Inc.'s r&d per share of $3.24 is higher than 81% of companies in the Health Care sector (FY2025). R&D per Share returned to growth in FY2025 after 2 years of decline, reaching $3.24.
Based on SEC 10-K filings.
3.24 in FY2025 with a 5-year CAGR of +18.2%. Top quartile in the Health Care sector.
Improved from $1.46 to $3.24 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- +30.3%
- 5-Year CAGR
- +18.2%
- 10-Year CAGR
- -
Sector benchmark
Top 19% in Health CareTop 19% of 108This company $3.24 Sector average $2.07
▼
+56.1% above sector average
Key checks
Key Insights
- In FY2025, r&d per share increased 145.6% year-over-year.
- Ranks #21 out of 108 companies in the Health Care sector.
- Lowest r&d per share in the period was in FY2019.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -1.77 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $3.24 | +145.6% |
| FY2024 | $1.32 | -9.5% |
| FY2023 | $1.46 | -0.5% |
| FY2022 | $1.46 | +52.4% |
| FY2021 | $0.96 | -31.6% |
| FY2020 | $1.40 | +800.2% |
| FY2019 | $0.16 | -62.0% |
| FY2018 | $0.41 | -5.6% |
| FY2017 | $0.44 | -10.9% |
| FY2016 | $0.49 | +104.5% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026